One possible reason is that, as we previously reported, lipotoxicity leads to impaired GLP-1 receptor signaling pathway in pancreatic beta cells, and improvements in lipid control (such as bezafibrate treatment) in mouse models of obesity and diabetes increase the efficacy of incretin-based therapy (15). Here, GLP1R is linked to obesity disorder.